What's Happening?
New research from the Salk Institute has revealed a novel mechanism by which microglia, the immune cells of the brain and spinal cord, contribute to the progression of Amyotrophic Lateral Sclerosis (ALS). Published in Nature Communications, the study
demonstrates that microglia utilize TAM receptors—a family of proteins discovered by senior author Greg Lemke, Ph.D.—to identify and eliminate living motor neurons in the spinal cords of mice with ALS. Traditionally, TAM receptors are known for clearing dead or dying cells. However, in the context of ALS, the study found that motor neurons in SOD1 mouse models (a common ALS model) display 'eat me' signals (phosphatidylserine) on their surface even when alive, prompting microglia to engulf them. When the Axl and Mer TAM proteins were disabled in these mice, they initially became sicker but ultimately lived longer, and the accumulation of microglia-eaten neurons was significantly reduced.
Why It's Important?
This discovery is crucial for understanding ALS and other neurodegenerative diseases, as it identifies an unexpected pathway for neuronal destruction. The finding that microglia actively consume living motor neurons, rather than just clearing debris, fundamentally changes the understanding of ALS progression. This mechanism could explain why microglial activation is strongly linked to the disease and how it contributes to its severity and lethality. Furthermore, the study has broader implications for molecular biology and immunology, as it marks the first time the TAM system has been shown to target living cells. This insight opens up new avenues for immunotherapy development, suggesting that TAM-based proteins could be engineered to target and eliminate specific unwanted living cells, such as cancer cells or autoimmune cells, offering a less invasive alternative to current cell-based immunotherapies.
What's Next?
The research team emphasizes that while these findings suggest targeting the TAM system, simply removing it is not the optimal solution due to its vital role throughout the body. Future research will focus on designing therapies that specifically target the underlying mechanisms of ALS and other neurodegenerative diseases, such as Alzheimer's or Parkinson's, in conjunction with modulating the TAM system. The insights gained into the TAM system, microglia, and neuronal biology will be invaluable for neurodegeneration research. Additionally, the discovery of TAM-based proteins' ability to induce 'eating' of living cells has already led to advancements in immunotherapy, with groups in Japan and Korea engineering such proteins to alleviate autoimmunity in lupus mice and reduce tumor growth in melanoma mice. This suggests a future where targeted TAM-based proteins could be designed to address a wide range of diseases by selectively eliminating specific cell types.
Beyond the Headlines
This study delves into the complex interplay between the immune system and neurological health, revealing a nuanced role for microglia that extends beyond simple waste removal. The ethical implications of manipulating a fundamental cellular 'eat me' signal are significant, requiring careful consideration in therapeutic development to ensure specificity and avoid unintended consequences. The finding that a system designed for clearing dead cells can be 'corrupted' to target living ones highlights the intricate and sometimes paradoxical nature of biological pathways. This research could also shift the paradigm in how neurodegenerative diseases are viewed, moving from solely focusing on neuronal pathology to a more integrated understanding that includes the active role of immune cells. The potential for engineering TAM-based proteins for targeted cell removal represents a profound shift in immunotherapy, offering a highly precise tool for treating diseases ranging from cancer to autoimmune disorders, with long-term societal impacts on disease management and quality of life.
